Revium Rx

Company Overview

Snapshot

Founded in June 2021 by Inna Martin, Revium Rx operates with 1–10 employees. The company is in its Pre-Funding stage and completed the acquisition of LipoVation Ltd. in February 2025, a strategic move to enhance its nanoparticle drug development capabilities.

Business overview

Revium Rx is a Health Tech & Life Sciences company focused on developing advanced delivery systems for therapeutics. Its core technology is a lipid-based platform designed to enhance and improve the potential of encapsulated therapeutics for hard-to-treat diseases. The company's pipeline includes solutions for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvants for solid tumors, and a novel immunization platform, serving the global pharmaceutical and healthcare markets.

Strategic signal

In February 2025, Revium Rx completed the acquisition of LipoVation Ltd., a move that significantly strengthens its position in nanoparticle drug development. This strategic acquisition signals Revium Rx's commitment to expanding its technological capabilities and pipeline, particularly in addressing critical areas like antibiotic resistance and cancer therapies, which could accelerate its R&D efforts and market penetration.

Company Intelligence Q&A

What is Revium Rx's core technological focus?

Revium Rx specializes in advanced lipid-based delivery systems designed to enhance the efficacy of encapsulated therapeutics for a variety of indications, including antimicrobial-resistant bacteria and solid tumors.

What significant corporate development did Revium Rx undertake in early 2025?

In February 2025, Revium Rx completed the acquisition of LipoVation Ltd. This strategic move is aimed at bolstering its capabilities in nanoparticle drug development.

What are some of the key therapeutic areas Revium Rx is targeting?

Revium Rx's current pipeline includes developing antibiotics for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvants for solid tumors, and a novel immunization platform.

What is the primary goal of Revium Rx's platform technology?

The primary goal of Revium Rx's platform is to expand the therapeutic horizons for hard-to-treat diseases by enhancing, improving, and unleashing the potential of encapsulated therapeutics.

What is the current product development stage for Revium Rx?

Revium Rx is currently in the R&D product stage, focusing on developing products such as Nano-Mupirocin and novel adjuvants for solid tumor therapies.